Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications-Reference-Cited by-同舟云学术

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

Published:2021-04 Issue:2 Volume:6 Page:100072
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Krebs M.G.,Blay J.-Y.,Le Tourneau C.,Hong D.,Veronese L.,Antoniou M.,Bennett I.

Funder

F Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents;Le Tourneau;Br J Cancer,2012

2. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture;Von Hoff;Clin Cancer Res,1998

3. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint;Mick;Control Clin Trials,2000

4. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers;Von Hoff;J Clin Oncol,2010

5. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers;Radovich;Oncotarget,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08

2. Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”;Journal of Modern Oncology;2023-12-10

3. Tumor-Agnostic Approvals: Insights and Practical Considerations;Clinical Cancer Research;2023-10-04

4. Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens;ESMO Open;2023-08

5. Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries;Personalized Medicine;2023-07